CD31 / PECAM-1

Anti-CD31 / PECAM-1 Monoclonal Antibody (Clone:MEM-05)-APC Conjugated

Antibodies Primary

Article No

30-1701-100

Species Reactivity

human

Size

100 Tests

Clone

MEM-05

Source / Host

mouse

Shipping Information

Blue Ice

Application

FC, WB

Article No

30-1701-100

Species Reactivity

human

Size

100 Tests

Clone

MEM-05

Source / Host

mouse

Shipping Information

Blue Ice

Application

FC, WB

Specifications

Application FC, WB
Article No 30-1701-100
Country Availability SE, FI, DK, NO, IS, EE, LV, LT
Clone MEM-05
Clone Type monoclonal
Conjugation APC
Description Anti-CD31 / PECAM-1 Monoclonal Antibody (Clone:MEM-05)-APC Conjugated
Supplier Abeomics
Entrez Gene ID 5175
Gene Symbol PECAM1
Immunogen Leukocytes of patient suffering from LGL-type leukaemia
Isotype IgG1
Notes CD31 (platelet endothelial cell adhesion molecule-1, PECAM-1) is an inhibitory coreceptor involved in regulation of T cell and B cell signaling by a dual immunoreceptor tyrosine-based inhibitory motif (ITIM) that upon associated kinases-mediated phosphorylation provide docking sites for protein-tyrosine phosphatases. CD31 is expressed ubiquitously within the vascular compartment and is located mainly at junctions between adjacent cells. N-terminal Ig-like domain of CD31 is responsible for its homophilic binding, which plays an important role in cell-cell interactions. CD31 is a multifunctional molecule with diverse roles in modulation of integrin-mediated cell adhesion, transendothelial migration, angiogenesis, apoptosis, negative regulation of immunoreceptor signaling, autoimmunity, macrophage phagocytosis, IgE-mediated anaphylaxis and thrombosis. It is one of key regulatory molecules in vascular system.
Alias Names PECAM1
Product Type Antibodies Primary
Shipping Information Blue Ice
Size 100 Tests
Source / Host mouse
Species Reactivity human
Storage 4°C
UniProt Number P16284
Product Page Updated 2024-02-06T07:35:53.072Z

Documentation

Shipping info
The delivery time for this item is approximately 5-8 business days. Read more